Mobile

Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Phase 2 Randomized Controlled Trial (RCT) Фаза 2,...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-001471-31

Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Phase 2 Randomized Controlled Trial (RCT) Фаза 2, многоцентрово, открито изпитване-продължение (ОИП) с ABT-122 при пациенти с ревматоиден артрит, които са завършили предхождащото M12-963 фаза 2 рандомизирано контролирано изпитване (РКИ)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to assess the long-term safety and tolerability of ABT-122 in subjects with rheumatoid arthritis (RA) who have completed Study M12-963 Phase 2 RCT.

Critère d'inclusion

  • Rheumatoid Arthritis

Liens